Biogen Seeks Return To Spinraza Growth As Competitors Also Pursue Dosing Advantages
Roche In Sales Lead, Novartis Follows In SMA
Sales of spinal muscular atrophy drug Spinraza had an unexpected US boost in Q4 and Biogen may win US FDA approval for a high dose version this year, but Roche’s Evrysdi was just approved in a new tablet formulation.
